Applied Therapeutics (NASDAQ:APLT) reported quarterly losses of $(0.96) per share. This is a 3.03 percent increase over losses of $(0.99) per share from the same period last year.
BioMarin To Present Data Showing Long-Term Benefit Of VOXZOGO On Growth In Children With Achondroplasia At 2023 European Society For Paediatric Endocrinology Meeting
Label Expansion Decisions Expected from U.S. and European Regulatory Authorities in Q4SAN RAFAEL, Calif., Sept. 21, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a global biotechnology company
